Thank you for sharing these. I'm glad to see that these studies and trials are happening.
One of my takeaways from the study you linked to on 'Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study', was the timing of the increased BMD of the hip.
The way I understand it, this seems to show that Romosozumab (Evenity) has the greatest impact on the hip in the last 6 months of treatment. I didn't realize this. If this is the case, it might be worth if for me to complete the full 12 consecutive months of treatment rather than breaking it up. I wish we knew more at this point.